Skip to main content

Table 1 Baseline characteristics of the study patients (N = 115)

From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data

Female, n (%)

97 (84.3)

Age, median (IQR)

50 (44.5–54)

Medical history, n (%)

 Smoking

23 (20.0)

 Alcohol abuse

10 (8.7)

 Family history of headaches

78 (67.8)

 Arterial hypertension

29 (25.2)

BMI, median (IQR)

23 (20–25)

Headache characteristics, n (%)

 Aura

19 (16.5)

 Allodynia

38 (33.0)

Pain characteristics, n (%)

 Unilateral

48 (41.7)

 Throbbing

74 (64.3)

 Diffuse

24 (20.9)

 Frontal

60 (52.2)

 Temporal

59 (51.3)

 Ocular

34 (29.6)

 Occipital

15 (13.0)

 Parietal

15 (13.0)

 Vertex

9 (7.8)

Medication overuse, n (%)

89 (77.4)

Preventive treatments in history, n (%)

 Antidepressants

82 (71.3)

 Anticonvulsants

69 (60.0)

 Calcium antagonists

42 (36.5)

 Other

8 (7.0)

Concurrent oral preventive treatments, n (%)

61 (53.0)

Migraine duration (years), median (IQR)

30 (22–39.5)

Chronic migraine duration (months), median (IQR)

62.5 (24–144)

  1. BMI indicates body mass index; IQR interquartile range